Own report: The coronavirus is gradually becoming more and more prevalent in myocardial infarction. More than 9,000 such patients have been recorded across the country. Liposomal amphotericin B, a drug used for primary treatment in this condition, is deficient in the country.

Mucormycosis is somewhat rarer and more deadly than any common fungal disease. In this situation, there is a danger of shortage of medicines in the country. The Delhi High Court has directed the central government to explain the reason for the shortage.

According to the doctors, the patients of the recovered Kovid-19 need to start the treatment of mucomycosis long before the body becomes weak. But drug shortages are hampering that treatment. This treatment lasts for 4 to 6 weeks. Whose main drug is amphotericin. In that case about 90 to 120 injections are required. The cost of treatment is about 5 to 6 lakh rupees.

Read more, The number of corona infections is increasing again in 24 hours, but the recovery rate is higher

In that case, each patient needs an average of 100 vials. In other words, about 9 to 10 lakh amphotericin injections are required in India as per the number of patients affected in the country at present. These drugs are manufactured by Serums and Vaccines, BDR Pharmaceuticals, Sun Pharma, Cipla and Life Care Innovations.

According to health experts, there are three types of drugs – liposomal amphotericin, lipid complex version and amphotericin B deoxycholate. Of these, side effects of liposomal amphotericin are less common in patients with comorbidities. So it has been chosen for treatment. But as the drug shortage in the country has increased, warnings have also been issued that there will be deaths due to drug shortage.